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(IDIBAPS), University of Barcelona, Villarroel, 170 08036 Barcelona, Spain. 
E-mail address: rsanchez@clinic.cat (R. Sanchez-Valle).   
1 These authors contributed equally. 
Contents lists available at ScienceDirect 
NeuroImage: Clinical 
journal homepage: www.elsevier.com/locate/ynicl 
https://doi.org/10.1016/j.nicl.2020.102540 
Received 23 June 2020; Received in revised form 14 December 2020; Accepted 15 December 2020   
NeuroImage: Clinical 29 (2021) 102540
2







A B S T R A C T   
Mutations in the granulin gene (GRN) cause familial frontotemporal dementia. Understanding the structural brain 
changes in presymptomatic GRN carriers would enforce the use of neuroimaging biomarkers for early diagnosis 
and monitoring. We studied 100 presymptomatic GRN mutation carriers and 94 noncarriers from the Genetic 
Frontotemporal dementia initiative (GENFI), with MRI structural images. We analyzed 3T MRI structural images 
using the FreeSurfer pipeline to calculate the whole brain cortical thickness (CTh) for each subject. We also 
perform a vertex-wise general linear model to assess differences between groups in the relationship between CTh 
and diverse covariables as gender, age, the estimated years to onset and education. We also explored differences 
according to TMEM106B genotype, a possible disease modifier. Whole brain CTh did not differ between carriers 
and noncarriers. Both groups showed age-related cortical thinning. The group-by-age interaction analysis 
showed that this age-related cortical thinning was significantly greater in GRN carriers in the left superior frontal 
cortex. TMEM106B did not significantly influence the age-related cortical thinning. Our results validate and 
expand previous findings suggesting an increased CTh loss associated with age and estimated proximity to 
symptoms onset in GRN carriers, even before the disease onset.   
1. Introduction 
Frontotemporal dementia (FTD) is a clinically, genetically and 
pathologically heterogeneous group of neurodegenerative diseases 
characterized by behavioral and language impairment. FTD is a highly 
heritable disorder, with mutations in several genes causing genetic 
forms of the disease. Mutations in the progranulin (GRN) gene were 
identified in 2006 as a cause of familial FTD with TAR-DNA binding 
protein 43 (TDP-43) inclusions (Baker et al., 2006; Cruts et al., 2006). 
The prevalence of GRN mutations has been estimated at 6% of all FTD 
patients and 20% of familial FTD (Cruts and Van Broeckhoven, 2008). 
The majority of FTD due to GRN mutations patients present a behavioral 
variant FTD, non-fluent primary progressive aphasia or corticobasal 
syndrome (Moore et al., 2019). 
In 2010, a genome-wide association study revealed transmembrane 
protein 106B (TMEM106B) gene as a risk factor for FTD with TDP-43 
inclusions (Van Deerlin et al., 2010). Further studies had replicated 
these findings, showing an extremely low presence of the TMEM106B 
minor allele in homozygosis in GRN patients, indicating that individuals 
who are homozygous for the minor TMEM106B allele are less likely to 
develop symptoms (Finch et al., 2011; Nicholson and Rademakers, 
2016). 
Previous work using structural MRI revealed that symptomatic GRN 
mutation carriers typically show a widespread but asymmetric pattern 
of grey matter (GM) loss, affecting frontal, temporal and parietal lobes 
(Beck et al., 2008; Fumagalli et al., 2018; Whitwell et al., 2009). Studies 
in presymptomatic GRN mutations carriers have shown divergent re-
sults, with many of them reporting no significant brain structural dif-
ferences compared with noncarriers (Borroni et al., 2012, 2008; 
Caroppo et al., 2015; Cash et al., 2018; Olm et al., 2018; Panman et al., 
2019; Pievani et al., 2014; Rohrer et al., 2015). TMEM106B variants 
have also been studied in the general population using neuroimaging, 
with the risk allele being related to reduced volume of the left temporal 
lobe in non-demented subjects (Adams et al., 2014). In this line, and 
complementing the structural findings, Premi et. al. used functional MRI 
and found that, in GRN carriers, the TMEM106B risk haplotype was 
associated with decreased functional connectivity in the left frontopar-
ietal network (Premi et al., 2014). 
In a previous cross-sectional study with a limited number of subjects, 
we observed that presymptomatic GRN mutation carriers presented 
greater loss of cortical thickness (CTh) by age in temporal areas 
compared to noncarriers (Moreno et al., 2013). Here, we aimed to 
expand these previous findings by investigating the change in CTh in a 
much larger cohort of presymptomatic mutation carriers using data from 
the Genetic Frontotemporal Dementia Initiative (GENFI). We also aimed 
to investigate the potential influence of the TMEM106B genotype in the 
grey matter loss in GRN carriers. 
2. Methods 
2.1. Participants 
We analyzed cross-sectional data from the GENFI study (Rohrer 
et al., 2015), Data Freeze 3. The GENFI cohort includes subjects at risk of 
genetic FTD, from centres across Europe and Canada (https://www. 
genfi.org/). Subjects in the cohort undergo a standardized clinical and 
neuropsychological assessment as well as an MRI exam once a year 
(Rohrer et al., 2013). Our work included the baseline data from 100 
presymptomatic mutation carriers and 94 noncarriers from 54 different 
families. For each subject, sex, age, estimated years to onset (EYO) and 
education were obtained from the GENFI database. The EYO was 
computed considering the difference between the subject’s age and the 
average familial age of symptom onset. Asymptomatic status was 
ascertained based on relative’s interview, neurological examination and 
normality on behavioral scales and neuropsychological tests. Local 
ethics committees at each site approved the study and all participants 
provided written informed consent. 
2.2. TMEM106B genetic analysis 
TMEM106B rs1990622 (C/T) single nucleotide polymorphism was 
performed according to standard procedures (Premi et al., 2014) in 90 
subjects: 46 presymptomatic GRN carriers and 44 noncarriers. 
2.3. Demographic and clinical statistical analysis 
Differences in the clinical and demographic data between carriers 
and presymptomatic carriers were assessed using t-test for continuous 
variables and chi-squared test was used for dichotomous data. Differ-
ences in demographics between TMEM106B genotypes were assessed 
with non-parametric tests (Fisher Test for dichotomous data and 
Kruskall-Wallis Test for continuous data). 
2.4. Image acquisition and processing 
Participants underwent a 1.1-mm isotropic resolution volumetric T1 
MR imaging on a 3 T using the sequences defined within the GENFI 
consortium. 
MRI images of all subjects were downloaded from GENFI database 
and processed using FreeSurfer version 6.0 (http://surfer.nmr.mgh.har 
vard.edu/), with the main goal of computing individual CTh surface 
maps. Briefly, the FreeSurfer pipeline includes skull stripping (Ségonne 
et al., 2004), segmentation of the subcortical white matter and deep gray 
matter volumetric structures (Fischl et al., 2004, 2002), tessellation of 
boundaries, and definition of the transition between tissue classes. Then, 
CTh is calculated as the closest distance from the gray/white boundary 
to the gray/cerebrospinal fluid boundary at each vertex (Dale et al., 
S. Borrego-Écija et al.                                                                                                                                                                                                                          
NeuroImage: Clinical 29 (2021) 102540
3
1999; Fischl and Dale, 2000). 
Individual CTh maps were visually inspected to detect and correct 
processing errors. From an initial sample of 114 presymptomatic mu-
tation carriers and 101 noncarriers, 21 subjects were excluded due to 
bad reconstruction or other FreeSurfer processing errors, resulting in the 
final sample of 100 presymptomatic carriers and 94 noncarriers. Surface 
maps were registered to the standard average space and smoothed with 
a Full Width at Half Maximum (FWHM) of 15 mm. 
2.5. Image-based statistics 
We first obtained whole brain CTh for each subject, calculated as the 
average CTh across all vertices (i.e., weighted average between the two 
hemispheres). This measure was correlated using Pearson’s coefficient 
with age to investigate global age-related trajectories in the two groups. 
Linear and non-linear regression models were explored in the whole 
group as showed in the Supplementary material to determine the asso-
ciation between the whole CTh and age (Supplementary material). Due 
the lack of difference between linear and non-linear models, we used 
vertex-wise general linear models as implemented in FreeSurfer to test 
differences between carriers and noncarriers as well as interaction with 
age at the regional level. We added sex, education and the scanner used 
as covariates. Homoscedasticity of the samples were assessed by the 
Non-Constant Variance Test. In addition to chronological age, we also 
assessed the effect on CTh of the EYO. All maps were corrected for 
multiple comparisons using precomputed Monte Carlo permutations 
with a significance threshold of p < 0.05 (for both thresholding and 
cluster significance), as implemented in Freesurfer. 
To study whether there were differences in asymptomatic carriers as 
they approached the predicted symptoms onset, we repeated the group 
comparison analysis (i.e., carriers vs non-carriers) using only the sub-
group of subjects that were closer to the disease onset (i.e. those with 
EYO > -10 years). 
Finally, we repeated the multiple linear regression adding the 
TMEM106B genotype as covariable. For this analysis, we assess the ROIs 
found significant different in the previous analyses. 
3. Results 
3.1. Demographic and genetic results 
The demographic and genetic data of the 194 subjects are described 
in Table 1. The mean age at onset of the 54 different families included 
was 60.1 years (range 43 – 74.5 years). There were no differences in age, 
EYO, sex or education between groups. On average, presymptomatic 
mutation carriers presented an EYO of − 13.0 years. No significant dif-
ferences were found in TMEM106B haplotypes between groups. In both 
groups, the homozygosity for the protective genotype (C/C) were rare 
(6.8% in noncarriers carriers and 6.2% in presymptomatic carriers). No 
differences in gender, age, EYO or education were found between the 
different TMEM106B genotypes. 
3.2. Group differences in cortical thickness 
There were no differences in CTh at the group level when comparing 
presymptomatic mutation carriers and noncarriers groups, neither with 
global measures nor with vertex-wise analyses. We hypothesized that 
this lack of difference might be consequence of the inclusion of subjects 
far from the predicted age at onset, and we also performed the whole- 
brain vertex-wise analysis between carriers and noncarriers in the sub-
group of subjects nearest to the expected onset (EYO > -10), but no 
significant differences arose. 
3.3. Correlation between cortical thickness and age 
When we evaluated the CTh correlation with age at the whole-brain 
level, both presymptomatic mutation carriers and noncarriers showed a 
pattern of cortical thinning associated with age (r = − 0.59 vs r = − 0.53, 
both significant with p < 0.001), but no significant differences were 
observed differences between them at the whole brain level (p = 0.272) 
(Fig. 1). 
3.4. Vertex-wise general linear models 
When comparing carriers and noncarriers at the vertex-wise level 
with an interaction model, we identified a cluster with significant results 
(corrected p < 0.05) in the left superior frontal cortex (Fig. 2A). Age, 
gender, education and scanner were included as covariates. When 
studying the trajectories separately for each group within the significant 
ROI, we found that presymptomatic carriers showed a significant 
negative correlation between age and CTh (r = − 0.57, p < 0.001), while 
noncarriers did not (r = − 0.12, p = 0.265) (Fig. 2B). Additionally, we 
performed a multiple linear regression model within the ROI to quantify 
the effect of age education and gender into this result. Only Age and Age 
× group interaction were significant (p < 0.001, see Table 2). 
3.5. Correlations between cortical thickness and EYO 
Due to the presence of different GRN mutations that may present 
different ages of onset, we repeated the interaction analysis using EYO 
instead of actual age. We identified a cluster with significant differences 
between carriers and noncarriers (corrected p < 0.05) covering the right 
temporal cortex, the banks of superior temporal sulcus, the inferi-
orparietal and the supramarginal gyrus. It is noticeable that these re-
gions also appeared in the analysis with age, however they did not 
survive multiple comparisons. Again, we performed multiple linear 
regression models to predict the ROI-CTh of these areas considering EYO 
(instead the age), we found similar results, with presymptomatic carriers 
presenting significant higher CTh loss by age than noncarriers (p <
0.01). Fig. 3 shows the correlation between CTh and EYO in both groups. 
(r = − 0.65 for carriers vs r = − 0.33 for noncarreirs, p < 0.01) (Fig. 3). 
3.6. Influence of the TMEM106B genotype in the CTh – Age relationship 
We did not find significant results at the vertex-wise level for the 
TMEM106B analyses for any of the comparisons tested. Therefore, we 
performed a hypothesis-driven study by focusing on the region that 
resulted significant in the age × group interaction. We divided the GRN 
carriers in groups according their TMEM106B genotype we found a 
significant negative correlation in the T/C carriers (r = − 0.52, p < 0.01) 
and the T/T carriers (r = − 0.47, p < 0.05), but not in the three subjects 
with the C/C genotype (r = –0.365, p = 0.762; Fig. 4). Only the corre-
lation of the T/C carriers was significant and showed statistical 
Table 1 
Demographic characteristics and TMEM106B genotype. EYO: Estimated Years to 
Onset, SD: standard deviation; ns: not significant, TMEM106B: transmembrane 
protein 106B.   
Noncarriers 








Age, years mean (SD) 47.5 (13.2) 46.8 (12.2) 0.595 
EYO, years mean (SD) − 13.2 
(14.9) 
− 13.0 (12.2) 0.967 
Sex male/female 51/43 65/35 0.141 
Education, years mean 
(SD) 
14.2 (3.8) 14.6 (3.6) 0.658 
TMEM106B 
(rs1990622) 
n ¼ 44 n ¼ 46  
C/C (%) 3 (6.8%) 3 (6.5%) 0.889 
C/T (%) 27 (61.4%) 26 (56.5%) 
T/T (%) 14 (31.8%) 17 (37.0%)  
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differences with the noncarriers group (p < 0.05). When we added the 
TMEM106B genotype as covariate to the multiple linear regression 
analysis we did not find any influence of this over the CTh, neither for 
presymptomatic carriers nor the noncarriers. 
4. Discussion 
In this study, we used data from the GENFI cohort to evaluate CTh in 
presymptomatic GRN mutation carriers. Although we did not find dif-
ferences between carriers and noncarriers at the group-wise comparison, 
we found differences in the influence of aging and estimated years to 
onset in CTh, suggesting a greater cortical loss in presymptomatic car-
riers as they approach the clinical onset. 
Several cross-sectional and longitudinal studies have evaluated GM 
loss in presymptomatic GRN mutation carriers with different method-
ologies, with partially divergent results. Our study, as most previous 
cross-sectional studies using structural MRI, did not find gray matter 
cortical thickness differences between presymtomatic GRN mutation 
carriers and controls (Borroni et al., 2012, 2008; Caroppo et al., 2015; 
Cash et al., 2018; Dopper et al., 2013; Fumagalli et al., 2018; Moreno 
et al., 2013; Panman et al., 2019). By contrast, few studies found gray 
matter atrophy pattern in presymptomatic carriers: Pievani and col-
leagues found greater GM loss in frontal areas, (Pievani et al., 2014) 
while Rohrer et. al. found significant differences between carriers and 
Fig. 1. Scatter plot showing correlation between whole CTh and age in presymptomatic GRN carriers (red) and noncarriers (blue). No statistical differences between 
trajectories were found. CTh: Cortical Thickness. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
Fig. 2. Relationship between CTh and age in the selected area of the cortex where significant differences between carriers and noncarriers where found: A) Brain 
maps showing the area with statistical differences between presymptomatic carriers and noncarriers (p < 0.05). B) Scatter plot showing relationship between CTh 
and age in presymptomatic GRN carriers (red) and noncarriers (blue) in the selected area. Lines represent estimated linear regression models for both groups. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 2 
Multiple linear regression model to predict CTh based on the presence of GRN 
mutation (presymptomatic carriers vs noncarriers) and age. Sex and education 
were added as covariates.   
β (95% CI) t value p value 
Intercept 3.021 (2.857, 3.185) 36.82  <0.001 
GRN 
Noncarriers vs carriers 
0.019 (− 0.025, 0.063) 0.85  0.393 
Age (years) − 0.008 (− 0.010, − 0.005 − 6.03  <0.001 
Education (years) 0.050 (− 0.001, 0.011) 1.68  0.094 
Gender 
Male vs female 
− 0.001 (− 0.046, 0.043) − 0–05  0.956 
Age × GRN 0.006 (0.003, 0.010) 3.50  <0.001  
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noncarriers in the insula 15 years before the expected onset, and in the 
temporal and parietal lobes 10 years before the expected onset (Rohrer 
et al., 2015). These discrepancies in the quantification of GM loss in 
presymptomatic GRN mutation carriers differ from the extensive GM 
atrophy observed in symptomatic mutation carriers, even with a visual 
inspection. Several explanations have been proposed to explain this 
divergence of results. First, in a group cross-sectional comparison, sub-
jects far from symptom onset are mixed with subjects close to disease 
onset; if CTh loss in GRN mutation carriers accelerates around the time 
of symptoms onset, mixing subjects at different intervals from symptom 
onset could cancel any apparent differences with noncarriers. In addi-
tion, the asymmetric pattern of atrophy in GRN mutation carriers might 
limit the differences in group-wise neuroimaging analyses. 
In a previous study, in a sample of 13 presymptomatic GRN mutation 
carriers we observed that presymptomatic carriers presented greater 
age-related cortical thinning in the temporal areas when compared with 
controls (Moreno et al., 2013). In the present study, we expand these 
previous results in a much larger cohort of subjects at risk of FTD due to 
mutations in GRN. We found that both, presymptomatic GRN carriers 
and noncarriers showed a negative correlation of their CTh with age, 
with older subjects presenting lesser CTh. With the interaction analysis, 
we found a group-by-age effect in the left superior frontal cortex. In 
addition, the results of the multiple linear model of our study showed 
that, in this area, the presymptomatic carriers showed significantly 
greater loss of CTh with age than noncarriers. It might suggest that 
presymtomatic GRN carriers suffer a greater neuronal loss in this area 
due to neurodegeneration rather than normal aging. This is an area 
particularly affected in symptomatic patients (Cash et al., 2018) that 
have also been found to have increased rates of atrophy in longitudinal 
studies with presymptomatic carriers (Caroppo et al., 2015; Chen et al., 
2019). 
Recent work suggests that EYO has limited value in GRN families, 
due to a weak correlation between the individual age at onset and family 
age at onset (Moore et al., 2019) but better predictive markers of the 
disease age of onset are still lacking. Thus, as the present sample in-
cludes different GRN mutations, we also investigate the effect of EYO in 
Fig. 3. Relationship between CTh and EYO: (A) Brain maps showing areas with statistical differences between carriers and noncarriers. B) Scatter plot illustrates the 
relationship between CTh and EYO in carriers and noncarriers. The X-axis represents the EYO. The Y-axis represents the mean CTh of the ROI covering all areas with 
significant differences between carriers and noncarriers. CTh: Cortical Thickness; EYO: estimated years to onset; ROI: Region of Interest. 
Fig. 4. Scatter plot showing relationship between CTh and age in GRN carriers according their TMEM106B genotype and noncarriers in the left superior fron-
tal cortex. 
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CTh in addition to the effect of the chronological age. When we study the 
correlation between CTh values and EYO, we found significant differ-
ences between presymptomatic GRN carriers and noncarriers in the 
right supramarginal gyrus and the banks of the rightsuperior temporal 
sulcus, similar to the area found in a previous work using only subjects 
with the same GRN mutation (Moreno et al., 2013) and thus, chrono-
logical age was interchangeable with EYO. Even if the localization of the 
significant clusters were not the same when EYO was used in the 
interaction analysis instead of age, we believe that both the dorso- 
frontal and the supramarginal/temporal gyrus areas are important in 
the disease, as they both appear at the uncorrected level. However, the 
fact that the magnitude of the effects is small the inclusion of a large 
number of covariates might hide some results when we corrected for 
multiple comparisons. 
Variants in the TMEM106B gene have been hypothesized to be a 
genetic modulator of risk for GRN carriers. Previous works suggests that 
TMEM106B minor allele in homozygosis (C/C in rs1990622) is protec-
tive or might delay the onset in individuals with pathogenic GRN mu-
tations. On this basis, we evaluate the influence of the TMEM106B 
genotype in our results. Despite the fact that we did not find differences 
between the different TMEM106B genotypes, we found a trend sug-
gesting that C/C carriers might present a lower loss of CTh by age than 
the T/C and T/T carriers in the left superior frontal cortex. The absence 
of statistical differences in these analyses may be consequence of the 
small sample of subjects carrying the C/C genotype in our series. This 
would be in consonance with previous works with functional MRI that 
found decreased brain connectivity within the middle frontal gyrus and 
the left frontoparietal network in GRN carriers with the risk TMEM106B 
allele in front those with the protective allele (Premi et al., 2014). 
The main strength of this study lies in the large sample of pre-
symptomatic subjects carrying mutations in GRN. We also acknowledge 
some limitations. First, our age-related results are based on cross- 
sectional rather than longitudinal data. Although our analysis suggests 
a faster atrophy in presymptomatic carriers, further studies with longi-
tudinal data are needed to corroborate this hypothesis. Another limita-
tion is the fact that our study includes different GRN mutations which 
may present different ages at symptom onset, and EYO was used in some 
of the analysis to overcome this limitation. Finally, the TMEM106B 
haplotype was not available in all subjects. This fact, combined with the 
low frequency of the C/C haplotype in our series, limit the validity of 
statistical analysis performed to evaluate the influence of the 
TMEM106B gene in GRN carriers. 
5. Conclusions 
In conclusion, despite no differences in CTh were found at the whole- 
group comparison, the proposed linear model showed that pre-
symtomatic GRN carriers present a significantly greater loss of CTh with 
age and proximity to expected disease onset. These findings suggest a 
faster process of neuronal loss in carriers, supporting that structural 
neuroimaging might be useful to monitor the effect of disease-modifying 
therapies even in presymptomatic phases of the disease. 
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